Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KADIAN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Mild to moderate pain,Fever
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily via CYP3A4; also undergoes N-demethylation to normorphine.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~30–35% bound, primarily to albumin
Approximately 10-20% bound to serum albumin; extensive tissue binding.
1.0–4.0 L/kg; wide distribution reflects extensive tissue uptake
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: ~20–40% due to extensive first-pass metabolism
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-60 m L/min: start with 75% of usual dose; GFR <30 m L/min: start with 50% of usual dose and increase cautiously.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: start with 50-75% of usual dose; Child-Pugh Class C: avoid or use with extreme caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for pediatric use; safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lower end of dosing range (e.g., 10-20 mg every 12 hours); monitor for respiratory depression and constipation; consider extended dosing intervals.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Cytochrome P450 3A4 interaction,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects,Seizures,Avoid in patients with known or suspected gastrointestinal obstruction, including paralytic ileus
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to morphine sulfate or any component of the product
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol and any products containing alcohol (e.g., alcoholic beverages, certain mouthwashes, over-the-counter liquid medications) as alcohol can increase the release rate of morphine from the extended-release formulation, risking overdose. Grapefruit juice may theoretically alter morphine metabolism; caution advised. High-fat meals may delay absorption but do not significantly affect overall exposure; take consistently with regard to meals.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
KADIAN (morphine sulfate extended-release) is classified as Pregnancy Category C. First trimester: risks are uncertain but opioid use has been associated with neural tube defects in some studies; however, data for morphine specifically are limited. Second and third trimesters: chronic use may lead to fetal dependence and withdrawal (neonatal abstinence syndrome). Near term: increased risk of respiratory depression in the neonate. Morphine crosses the placenta.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Morphine is excreted into breast milk. The M/P ratio is approximately 2.5:1 for morphine. Breastfeeding is generally considered compatible with caution; monitor infant for respiratory depression, sedation, and withdrawal symptoms. American Academy of Pediatrics considers morphine compatible with breastfeeding, but advise using lowest effective dose for shortest duration.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy may increase clearance of morphine due to increased renal blood flow and volume of distribution, potentially requiring higher doses to achieve analgesia. However, no standardized dose adjustments; dose should be individualized based on pain control and side effects. Taper if discontinuing to avoid withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
KADIAN is an extended-release morphine formulation requiring q12h dosing; capsules can be opened and sprinkled on applesauce but should not be crushed or chewed. Given the high opioid content, use with caution in opioid-naïve patients; start with lowest available strength. Monitor for respiratory depression, especially during titration. KADIAN levels may be affected by hepatic impairment; reduce dose in moderate to severe hepatic disease. Do not use for as-needed analgesia.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take KADIAN exactly every 12 hours; do not take more frequently.,Swallow capsules whole; if you have trouble, open the capsule and sprinkle the beads onto a small amount of applesauce and swallow immediately without chewing.,Do not crush, chew, or dissolve the capsule contents as that can cause a fatal overdose.,Avoid alcohol and any medicines containing alcohol while taking KADIAN.,Store securely out of reach of children and others; dispose of unused pills via a take-back program.,Do not stop taking abruptly; consult your doctor for a tapering schedule.,Contact your healthcare provider if you experience severe drowsiness, confusion, or difficulty breathing.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KADIAN vs ACEPHEN, answered by our medical review team.
KADIAN is a Opioid Analgesic that works by Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KADIAN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KADIAN is: 20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KADIAN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KADIAN is classified as Category C. KADIAN (morphine sulfate extended-release) is classified as Pregnancy Category C. First trimester: risks are uncertain but opioid use has been associated with neural tube defects i. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.